Analyst Reco. Ascendis Pharma A/S

Equities

ASND

US04351P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
143.2 ^USD	-1.14%		+0.71%	+13.68%

Apr. 24	Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism	MT
Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating	Apr. 02	MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating	Mar. 15	MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating	Feb. 08	MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating	Feb. 08	MT
Cantor Fitzgerald Adjusts Price Target on Ascendis Pharma to $173 From $152, Keeps Overweight Rating	Feb. 06	MT
Wedbush Raises Price Target on Ascendis Pharma to $207 From $202, Maintains Outperform Rating	Jan. 08	MT
Wedbush Raises Ascendis Pharma's PT to $202 From $200, Keeps Outperform Rating; Says Among Top Picks for 2024	Dec. 20	MT
Jefferies Starts Ascendis Pharma With Buy Rating, $150 Price Target	Dec. 20	MT
Wells Fargo Adjusts Ascendis Pharma Price Target to $149 From $137, Maintains Overweight Rating	Dec. 19	MT
Wedbush Adjusts Ascendis Pharma A/S Price Target to $200 From $192, Maintains Outperform Rating	Nov. 20	MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $116 From $113, Maintains Equalweight Rating	Nov. 09	MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $113 From $109, Maintains Equalweight Rating	23-09-06	MT
Wedbush Raises Ascendis Pharma's Price Target to $192 From $187 After Model Adjustments, Keeps Outperform Rating	23-09-06	MT
Wedbush Lifts Ascendis Pharma's Price Target to $187 From $186, Keeps Outperform Rating	23-06-02	MT
Wedbush Lowers Ascendis Pharma's Price Target to $186 From $195 After Model Adjustments, Keeps Outperform Rating	23-05-08	MT
Morgan Stanley Adjusts Ascendis Pharma's Price Target to $109 From $107, Keeps Equalweight Rating	23-04-28	MT
Credit Suisse Raises Ascendis Pharma's Price Target to $89 From $82 After Q1 Skytrofa Revenue Beat Consensus, Keeps Neutral Rating	23-04-28	MT
Oppenheimer Downgrades Ascendis Pharma to Perform From Outperform, Removes $148 Price Target	23-04-05	MT
Citigroup Adjusts Ascendis Pharma Price Target to $146 From $163, Maintains Buy Rating	23-04-05	MT
Morgan Stanley Downgrades Ascendis Pharma to Equalweight From Overweight, Adjusts Price Target to $108 From $151	23-04-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Ascendis Pharma A/S

Equities

ASND

US04351P1012

Analyst Reco.

Filters